Updated international consensus report on the investigation and management of primary immune thrombocytopenia

Provan, 2010, International consensus report on the investigation and management of primary immune thrombocytopenia, Blood, 115, 168, 10.1182/blood-2009-06-225565 Neunert, 2011, The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia, Blood, 117, 4190, 10.1182/blood-2010-08-302984 Vernooij, 2017, Reporting items for updated clinical guidelines: Checklist for the Reporting of Updated Guidelines (CheckUp), PLoS Med, 14, e1002207, 10.1371/journal.pmed.1002207 Arnold, 2017, Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry, Blood Adv, 1, 2414, 10.1182/bloodadvances.2017010942 Tamminga, 2009, Possible lower rate of chronic ITP after IVIG for acute childhood ITP an analysis from registry I of the Intercontinental Cooperative ITP Study Group (ICIS), Br J Haematol, 146, 180, 10.1111/j.1365-2141.2009.07743.x Miller, 2001, Idiopathic thrombocytopenic purpura and MMR vaccine, Arch Dis Child, 84, 227, 10.1136/adc.84.3.227 Grimaldi-Bensouda, 2012, A case-control study to assess the risk of immune thrombocytopenia associated with vaccines, Blood, 120, 4938, 10.1182/blood-2012-05-431098 Grimaldi-Bensouda, 2016, Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome, Haematologica, 101, 1039, 10.3324/haematol.2016.146373 Newton, 2011, Fatigue in adult patients with primary immune thrombocytopenia, Eur J Haematol, 86, 420, 10.1111/j.1600-0609.2011.01587.x Kuter, 2012, Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care, Am J Hematol, 87, 558, 10.1002/ajh.23163 Hill, 2015, Fatigue in immune thrombocytopenia, Br J Haematol, 170, 141, 10.1111/bjh.13385 Mant, 1979, Severe thrombocytopenia probably due to acute folic acid deficiency, Crit Care Med, 7, 297, 10.1097/00003246-197907000-00002 Mishra, 2015, Vitamin B12 and vitamin D deficiencies: an unusual cause of fever, severe hemolytic anemia and thrombocytopenia, J Family Med Prim Care, 4, 145, 10.4103/2249-4863.152276 Braester, 2003, Pseudothrombocytopenia as a pitfall in the treatment of essential thrombocythemia, Eur J Haematol, 70, 251, 10.1034/j.1600-0609.2003.00033.x George, 1996, Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology, Blood, 88, 3, 10.1182/blood.V88.1.3.3 British Committee for Standards in Haematology General Haematology Task Force, 2003, Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy, Br J Haematol, 120, 574, 10.1046/j.1365-2141.2003.04131.x Mak, 2000, The management of isolated thrombocytopenia in Chinese adults: does bone marrow examination have a role at presentation?, Clin Lab Haematol, 22, 355, 10.1046/j.1365-2257.2000.00340.x Jubelirer, 2002, The role of the bone marrow examination in the diagnosis of immune thrombocytopenic purpura: case series and literature review, Clin Appl Thromb Hemost, 8, 73, 10.1177/107602960200800110 Mittal, 2008, A high rate of CLL phenotype lymphocytes in autoimmune hemolytic anemia and immune thrombocytopenic purpura, Haematologica, 93, 151, 10.3324/haematol.11822 Rizvi, 2015, United Kingdom immune thrombocytopenia registry: retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenia and correlation with clinical findings, Br J Haematol, 169, 590, 10.1111/bjh.13330 Brynes, 2017, A 2-year, longitudinal, prospective study of the effects of eltrombopag on bone marrow in patients with chronic immune thrombocytopenia, Acta Haematol, 137, 66, 10.1159/000452992 Janssens, 2016, Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia, Ann Hematol, 95, 1077, 10.1007/s00277-016-2682-2 Stasi, 2009, Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review, Blood, 113, 1231, 10.1182/blood-2008-07-167155 Liebman, 2007, Secondary immune thrombocytopenic purpura, Curr Opin Hematol, 14, 557, 10.1097/MOH.0b013e3282ab9904 Aledort, 2004, Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies, Am J Hematol, 76, 205, 10.1002/ajh.20104 Brighton, 1996, Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias, Blood, 88, 194, 10.1182/blood.V88.1.194.194 McMillan, 2003, Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP), J Thromb Haemost, 1, 485, 10.1046/j.1538-7836.2003.00091.x Chan, 2003, The IgG subclasses of platelet-associated autoantibodies directed against platelet glycoproteins IIb/IIIa in patients with idiopathic thrombocytopenic purpura, Br J Haematol, 122, 818, 10.1046/j.1365-2141.2003.04509.x Al-Samkari, A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia, Am J Hematol. Stasi, 1994, Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura, Blood, 84, 4203, 10.1182/blood.V84.12.4203.bloodjournal84124203 Kim, 2013, Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies, Br J Haematol, 161, 706, 10.1111/bjh.12318 Pierrot-Deseilligny Despujol, 2008, Antiphospholipid antibodies in adults with immune thrombocytopenic purpura, Br J Haematol, 142, 638, 10.1111/j.1365-2141.2008.07228.x Ruggeri, 2014, Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors, J Thromb Haemost, 12, 1266, 10.1111/jth.12636 Altintas, 2007, Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura, J Thromb Thrombolysis, 24, 163, 10.1007/s11239-007-0031-y Moulis, 2017, Newly diagnosed immune thrombocytopenia adults: clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort, Am J Hematol, 92, 493, 10.1002/ajh.24702 Khellaf, 2014, Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies, Am J Hematol, 89, 194, 10.1002/ajh.23609 Vianelli, 2013, Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years, Haematologica, 98, 875, 10.3324/haematol.2012.075648 Guan, 2017, Long-term results of splenectomy in adult chronic immune thrombocytopenia, Eur J Haematol, 98, 235, 10.1111/ejh.12821 Rodeghiero, 2018, A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP, Br J Haematol, 181, 183, 10.1111/bjh.15090 Liebman, 2007, Other immune thrombocytopenias, Semin Hematol, 44, S24, 10.1053/j.seminhematol.2007.11.004 O’Leary, 2012, The risk of immune thrombocytopenic purpura after vaccination in children and adolescents, Pediatrics, 129, 248, 10.1542/peds.2011-1111 Makar, 2013, Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists, Am J Hematol, 88, 1041, 10.1002/ajh.23562 Al-Samkari, 2018, Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia, Am J Hematol, 93, 1501, 10.1002/ajh.25275 Abe, 2006, A simple technique to determine thrombopoiesis level using immature platelet fraction (IPF), Thromb Res, 118, 463, 10.1016/j.thromres.2005.09.007 Cybulska, 2017, Measurements of immature platelets with haematology analysers are of limited value to separate immune thrombocytopenia from bone marrow failure, Br J Haematol, 177, 612, 10.1111/bjh.14628 Levi, 2009, Guidelines for the diagnosis and management of disseminated intravascular coagulation, Br J Haematol, 145, 24, 10.1111/j.1365-2141.2009.07600.x Bianchi, 2002, Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura, Blood, 100, 710, 10.1182/blood-2002-02-0344 Rodeghiero, 2009, Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group, Blood, 113, 2386, 10.1182/blood-2008-07-162503 Boyle, 2013, Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia, Blood, 121, 4782, 10.1182/blood-2012-12-467068 Piel-Julian, 2018, Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults, J Thromb Haemost, 16, 1830, 10.1111/jth.14227 Portielje, 2001, Morbidity and mortality in adults with idiopathic thrombocytopenic purpura, Blood, 97, 2549, 10.1182/blood.V97.9.2549 Taylor, 2017, Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond, Br J Haematol, 177, 475, 10.1111/bjh.14564 Marshall, 2015, Romiplostim in the management of the thrombocytopenic surgical patient, Transfusion, 55, 2505, 10.1111/trf.13181 Al-Samkari, 2018, Romiplostim for the management of perioperative thrombocytopenia, Br J Haematol, 182, 106, 10.1111/bjh.15280 Cohen, 2000, The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts, Arch Intern Med, 160, 1630, 10.1001/archinte.160.11.1630 Kuter, 2019, Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies, Br J Haematol, 185, 503, 10.1111/bjh.15803 Cuker, 2016, How I treat refractory immune thrombocytopenia, Blood, 128, 1547, 10.1182/blood-2016-03-603365 Mahévas, 2016, How we manage immune thrombocytopenia in the elderly, Br J Haematol, 173, 844, 10.1111/bjh.14067 Shulman, 1965, The role of the reticuloendothelial system in the pathogenesis of idiopathic thrombocytopenic purpura, Trans Assoc Am Physicians, 78, 374 Gernsheimer, 1989, Mechanisms of response to treatment in autoimmune thrombocytopenic purpura, N Engl J Med, 320, 974, 10.1056/NEJM198904133201505 Kitchens, 1975, Ultrastructural changes of endothelium associated with thrombocytopenia, Blood, 46, 567, 10.1182/blood.V46.4.567.567 Kitchens, 1977, Amelioration of endothelial abnormalities by prednisone in experimental thrombocytopenia in the rabbit, J Clin Invest, 60, 1129, 10.1172/JCI108864 Matschke, 2016, A randomized trial of daily prednisone versus pulsed dexamethasone in treatment-naive adult patients with immune thrombocytopenia: EIS 2002 Study, Acta Haematol, 136, 101, 10.1159/000445420 Nakazaki, 2012, Comparison between pulsed high-dose dexamethasone and daily corticosteroid therapy for adult primary immune thrombocytopenia: a retrospective study, Intern Med, 51, 859, 10.2169/internalmedicine.51.7005 Praituan, 2009, Faster platelet recovery by high-dose dexamethasone compared with standard-dose prednisolone in adult immune thrombocytopenia: a prospective randomized trial, J Thromb Haemost, 7, 1036, 10.1111/j.1538-7836.2009.03359.x Bilgir, 2011, Comparison of conventional dose steroid treatment and high dose steroid treatment as run-in regime for splenectomy in immune thrombocytopenic purpura (ITP), Transfus Apheresis Sci, 44, 239, 10.1016/j.transci.2011.04.007 Naithani, 2010, High dose dexamethasone therapy shows better responses in acute immune thrombocytopenia than in chronic immune thrombocytopenia, Platelets, 21, 270, 10.3109/09537101003637257 Sakamoto, 2014, Prednisone versus high-dose dexamethasone for untreated primary immune thrombocytopenia. A retrospective study of the Japan Hematology & Oncology Clinical Study Group, J Thromb Thrombolysis, 37, 279, 10.1007/s11239-013-0939-3 Wei, 2016, High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial, Blood, 127, 296, 10.1182/blood-2015-07-659656 Mithoowani, 2016, High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis, Lancet Haematol, 3, e489, 10.1016/S2352-3026(16)30109-0 Gómez-Almaguer, 2013, High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia, Eur J Haematol, 90, 494, 10.1111/ejh.12102 Gudbrandsdottir, 2013, Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia, Blood, 121, 1976, 10.1182/blood-2012-09-455691 Zaja, 2010, Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia, Blood, 115, 2755, 10.1182/blood-2009-07-229815 Chapin, 2016, Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia, Am J Hematol, 91, 907, 10.1002/ajh.24434 Bussel, 2014, Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration, Haematologica, 99, 1264, 10.3324/haematol.2013.103291 Chugh, 2015, Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis, Lancet Haematol, 2, e75, 10.1016/S2352-3026(15)00003-4 Alpdogan, 1998, Efficacy of high-dose methylprednisolone as a first-line therapy in adult patients with idiopathic thrombocytopenic purpura, Br J Haematol, 103, 1061, 10.1046/j.1365-2141.1998.01096.x von dem Borne, 1988, High dose intravenous methylprednisolone or high dose intravenous gammaglobulin for autoimmune thrombocytopenia, Br Med J (Clin Res Ed), 296, 249, 10.1136/bmj.296.6617.249-a Kovaleva, 2016, Safety and efficacy of a 10% intravenous immunoglobulin preparation in patients with immune thrombocytopenic purpura: results of two international, multicenter studies, Immunotherapy, 8, 1371, 10.2217/imt-2016-0088 Spadaro, 2017, Rapid infusions of human normal immunoglobulin 50 g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia [published correction appears in Int Immunopharmacol. 2018;57:201], Int Immunopharmacol, 44, 38, 10.1016/j.intimp.2016.12.030 Frenzel, 2016, Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials, Int J Clin Pharmacol Ther, 54, 847, 10.5414/CP202782 Robak, 2010, Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam® 10%) in patients with immune thrombocytopenia, Hematology, 15, 351, 10.1179/102453310X12719010991867 Robak, 2009, Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura, Hematology, 14, 227, 10.1179/102453309X439773 Dash, 2014, Safety and efficacy of Gammaplex® in idiopathic thrombocytopenic purpura (ClinicalTrials.gov--NCT00504075), PLoS One, 9, e96600, 10.1371/journal.pone.0096600 Peng, 2014, Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study, J Thromb Haemost, 12, 497, 10.1111/jth.12524 Paziana, 2013, Ciclosporin use during pregnancy, Drug Saf, 36, 279, 10.1007/s40264-013-0034-x Go, 2007, The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia, Haematologica, 92, 283, 10.3324/haematol.10667 al-Samkari, 2018, Antiplatelet antibody testing in immune thrombocytopenia and Evan’s syndrome: longitudinal serological evolution and relation to clinical features, Blood, 132, 1137, 10.1182/blood-2018-99-118403 Naithani, 2009, Efficacy and safety of anti-D for treatment of adults with immune thrombocytopenia, Platelets, 20, 525, 10.3109/09537100903144617 Saol Therapeutics Inc Despotovic, 2012, RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME), Transfusion, 52, 1126, 10.1111/j.1537-2995.2011.03384.x Stirnemann, 2016, Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients, Eur J Haematol, 96, 269, 10.1111/ejh.12586 Khellaf, 2005, Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count, Haematologica, 90, 829 Rodeghiero, 2013, Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group, Blood, 121, 2596, 10.1182/blood-2012-07-442392 Goel, 2019, Platelet transfusion practices in immune thrombocytopenia related hospitalizations, Transfusion, 59, 169, 10.1111/trf.15069 Estcourt, 2017, Guidelines for the use of platelet transfusions, Br J Haematol, 176, 365, 10.1111/bjh.14423 Carr, 1986, Efficacy of platelet transfusions in immune thrombocytopenia, Am J Med, 80, 1051, 10.1016/0002-9343(86)90664-9 Spahr, 2008, Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients, Am J Hematol, 83, 122, 10.1002/ajh.21060 Park, 2016, Clinical efficacy and tolerability of vincristine in splenectomized patients with refractory or relapsed immune thrombocytopenia: a retrospective single-center study, Int J Hematol, 103, 180, 10.1007/s12185-015-1903-0 Ahn, 1984, Slow infusion of vinca alkaloids in the treatment of idiopathic thrombocytopenic purpura, Ann Intern Med, 100, 192, 10.7326/0003-4819-100-2-192 Ahn, 1974, Vincristine therapy of idiopathic and secondary thrombocytopenias, N Engl J Med, 291, 376, 10.1056/NEJM197408222910802 Facon, 1994, A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura: a report on 42 patients, Br J Haematol, 86, 678, 10.1111/j.1365-2141.1994.tb04810.x Fenaux, 1990, Slow infusions of vinblastine in the treatment of adult idiopathic thrombocytopenic purpura: a report on 43 cases, Blut, 60, 238, 10.1007/BF01728791 Fresneau, 2011, Vinblastine in the treatment of children and adolescents with refractory immune thrombocytopenia, Am J Hematol, 86, 785, 10.1002/ajh.22081 Manoharan, 1991, Targeted-immunosuppression with vincristine infusion in the treatment of immune thrombocytopenia, Aust N Z J Med, 21, 405, 10.1111/j.1445-5994.1991.tb01339.x Massimo, 1977, More on vincristine in treatment of ITP in children, N Engl J Med, 297, 397, 10.1056/NEJM197708182970718 Nomura, 1990, Clinical usefulness of vinca alkaloid slow infusion in the treatment of chronic refractory idiopathic thrombocytopenic purpura: a multicenter cooperative study, Nippon Ketsueki Gakkai Zasshi, 53, 98 Pizzuto, 1984, Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis, Blood, 64, 1179, 10.1182/blood.V64.6.1179.1179 Sikorska, 2004, The use of vinca alkaloids in adult patients with refractory chronic idiopathic thrombocytopenia, Clin Lab Haematol, 26, 407, 10.1111/j.1365-2257.2004.00643.x Stirnemann, 2012, The French Gaucher’s disease registry: clinical characteristics, complications and treatment of 562 patients, Orphanet J Rare Dis, 7, 77, 10.1186/1750-1172-7-77 Boruchov, 2007, Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP), Blood, 110, 3526, 10.1182/blood-2007-01-065763 Wardrop, 2013, Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders, Cochrane Database Syst Rev, CD009733 Newland, 2016, Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study, Br J Haematol, 172, 262, 10.1111/bjh.13827 Stasi, 2008, Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management, Thromb Haemost, 99, 4, 10.1160/TH07-08-0513 Sailer, 2006, The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy, Haematologica, 91, 1041 Marshall, 2016, Remissions after long-term use of romiplostim for immune thrombocytopenia, Haematologica, 101, e476, 10.3324/haematol.2016.151886 Wong, 2017, Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study, Blood, 130, 2527, 10.1182/blood-2017-04-748707 DOPTELET, 2019, DOPTELET® (avatrombopag) tablets, for oral use 2018, Nplate. Nplate (romiplostim) NPLATE, 2018, NPLATE® (romiplostim) for injection, for subcutaneous use PROMACTA, 2018, PROMACTA® (eltrombopag) tablets, for oral use; PROMACTA® (eltrombopag) for oral suspension Cines, 2017, Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia, Haematologica, 102, 1342, 10.3324/haematol.2016.161968 Sarpatwari, 2010, Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database, Haematologica, 95, 1167, 10.3324/haematol.2009.018390 Gernsheimer, 2010, Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP), J Thromb Haemost, 8, 1372, 10.1111/j.1538-7836.2010.03830.x Janssens, 2015, Romiplostim treatment in adults with immune thrombocytopenia of varying duration and severity, Acta Haematol, 134, 215, 10.1159/000381657 Stasi, 2012, Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care, Int J Hematol, 96, 26, 10.1007/s12185-012-1088-8 Shirasugi, 2012, An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP), Int J Hematol, 95, 652, 10.1007/s12185-012-1065-2 Shirasugi, 2011, Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized phase III clinical trial, Int J Hematol, 94, 71, 10.1007/s12185-011-0886-8 Pullarkat, 2009, Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531), Am J Hematol, 84, 538, 10.1002/ajh.21463 Kuter, 2013, Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy, Br J Haematol, 161, 411, 10.1111/bjh.12260 Kuter, 2010, Romiplostim or standard of care in patients with immune thrombocytopenia, N Engl J Med, 363, 1889, 10.1056/NEJMoa1002625 Michel, 2015, Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia, Ann Hematol, 94, 1973, 10.1007/s00277-015-2485-x Steurer, 2017, A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice, Eur J Haematol, 98, 112, 10.1111/ejh.12807 Bussel, 2009, Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP, Blood, 113, 2161, 10.1182/blood-2008-04-150078 Cines, 2015, Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim, Int J Hematol, 102, 259, 10.1007/s12185-015-1837-6 Park, 2016, Multicenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia, Int J Hematol, 103, 44, 10.1007/s12185-015-1889-7 Khellaf, 2011, Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program, Blood, 118, 4338, 10.1182/blood-2011-03-340166 Khellaf, 2013, A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia, Haematologica, 98, 881, 10.3324/haematol.2012.074633 Kuter, 2008, Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial, Lancet, 371, 395, 10.1016/S0140-6736(08)60203-2 Al-Samkari, 2018, An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia, Br J Clin Pharmacol, 84, 2673, 10.1111/bcp.13717 2018, Revolade. Revolade (olamine) González-López, 2017, Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice, Int J Hematol, 106, 508, 10.1007/s12185-017-2275-4 Tomiyama, 2012, A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia, J Thromb Haemost, 10, 799, 10.1111/j.1538-7836.2012.04695.x Yang, 2017, Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia, Br J Haematol, 176, 101, 10.1111/bjh.14380 Scully, 2012, Eltrombopag named patient programme for patients with chronic immune thrombocytopenia, Br J Haematol, 157, 259, 10.1111/j.1365-2141.2011.08954.x Tarantino, 2013, Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia, Blood Coagul Fibrinolysis, 24, 284, 10.1097/MBC.0b013e32835fac99 Katsutani, 2013, Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study, Int J Hematol, 98, 323, 10.1007/s12185-013-1401-1 Kuter, 2015, Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim, Int J Hematol, 101, 255, 10.1007/s12185-014-1731-7 Cheng, 2011, Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study, Lancet, 377, 393, 10.1016/S0140-6736(10)60959-2 Bussel, 2009, Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial, Lancet, 373, 641, 10.1016/S0140-6736(09)60402-5 Bussel, 2013, Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP), Br J Haematol, 160, 538, 10.1111/bjh.12169 González-López, 2016, Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice, Eur J Haematol, 97, 297, 10.1111/ejh.12725 Brynes, 2015, Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: data from the EXTEND study, Am J Hematol, 90, 598, 10.1002/ajh.24011 González-López, 2015, Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia, Am J Hematol, 90, E40, 10.1002/ajh.23900 Fukushima-Shintani, 2008, AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis, Exp Hematol, 36, 1337, 10.1016/j.exphem.2008.04.020 Fukushima-Shintani, 2009, AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist, Eur J Haematol, 82, 247, 10.1111/j.1600-0609.2008.01198.x Al-Samkari, 2018, Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia, Br J Haematol, 183, 168, 10.1111/bjh.15432 Kuter, 2018, Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies, Br J Haematol, 183, 466, 10.1111/bjh.15574 Bussel, 2014, A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia, Blood, 123, 3887, 10.1182/blood-2013-07-514398 Jurczak, 2018, Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia, Br J Haematol, 183, 479, 10.1111/bjh.15573 Patel, 2012, Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia, Blood, 119, 5989, 10.1182/blood-2011-11-393975 Al Askar, 2018, Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience, Int J Hematol, 107, 69, 10.1007/s12185-017-2325-y Miyakawa, 2015, Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy, Int J Hematol, 102, 654, 10.1007/s12185-015-1887-9 Marangon, 2017, Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response, Eur J Haematol, 98, 371, 10.1111/ejh.12839 Červinek, 2012, Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice, Int J Hematol, 96, 594, 10.1007/s12185-012-1206-7 Pasa, 2009, The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura, J Thromb Thrombolysis, 27, 329, 10.1007/s11239-008-0208-z Ghanima, 2015, Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial, Lancet, 385, 1653, 10.1016/S0140-6736(14)61495-1 Khellaf, 2014, Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients, Blood, 124, 3228, 10.1182/blood-2014-06-582346 Arnold, 2012, A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia, Blood, 119, 1356, 10.1182/blood-2011-08-374777 Mahévas, 2013, Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia, Am J Hematol, 88, 858, 10.1002/ajh.23518 Tran, 2014, A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study), Br J Haematol, 167, 243, 10.1111/bjh.13029 Zaja, 2010, Low-dose rituximab in adult patients with primary immune thrombocytopenia, Eur J Haematol, 85, 329, 10.1111/j.1600-0609.2010.01486.x Zaja, 2012, Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia, Am J Hematol, 87, 886, 10.1002/ajh.23272 Serris, 2018, Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: a multicenter retrospective cohort study of 71 adults, Am J Hematol, 93, 424, 10.1002/ajh.24999 RITUXAN, 2018, RITUXAN® (rituximab) injection, for intravenous use MabThera, 2018, MabThera (rituximab) Deshayes, Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: results at 5 years from the French prospective registry ITP-ritux [published online ahead of print 5 September 2019], Am J Hematol Gracie, 2018, Comparison of standard and low dose rituximab in primary immune thrombocytopenia: data from the UK ITP Registry, EHA Library, 214559, S139 Nazi, 2013, The effect of rituximab on vaccine responses in patients with immune thrombocytopenia, Blood, 122, 1946, 10.1182/blood-2013-04-494096 TAVALISSE, 2018, TAVALISSE™ (fostamatinib disodium hexahydrate) tablets, for oral use Bussel, 2018, Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials, Am J Hematol, 93, 921, 10.1002/ajh.25125 Bussel, 2019, Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program, Am J Hematol, 94, 546, 10.1002/ajh.25444 Dammika, 2016, Identifying the characteristics, natural behavioral pattern, and response to therapy in ITP in a multi-center population in Sri Lanka, Hematology, 21, 375, 10.1080/10245332.2016.1148845 Wang, 2012, A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia, Int J Hematol, 96, 222, 10.1007/s12185-012-1124-8 Liu, 2016, The effect of danazol in primary immune thrombocytopenia: an analysis of a large cohort from a single center in China, Clin Appl Thromb Hemost, 22, 727, 10.1177/1076029615622002 Zaja, 2012, Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab, Am J Hematol, 87, 321, 10.1002/ajh.22266 Colella, 2018, A retrospective analysis of 122 immune thrombocytopenia patients treated with dapsone: efficacy, safety and factors associated with treatment response, Blood, 132, 737, 10.1182/blood-2018-99-116467 Colović, 2011, Mycophenolate mophetil therapy for chronic immune thrombocytopenic purpura resistant to steroids, immunosuppressants, and/or splenectomy in adults, Platelets, 22, 153, 10.3109/09537104.2010.520372 Taylor, 2015, Mycophenolate mofetil therapy for severe immune thrombocytopenia, Br J Haematol, 171, 625, 10.1111/bjh.13622 Hasan, 2009, Repeated courses of rituximab in chronic ITP: three different regimens, Am J Hematol, 84, 661, 10.1002/ajh.21512 Chen, 2011, Laparoscopic splenectomy for patients with immune thrombocytopenia and very low platelet count: is platelet transfusion necessary?, J Surg Res, 170, e225, 10.1016/j.jss.2011.06.031 Zaja, 2016, Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study, Am J Hematol, 91, E293, 10.1002/ajh.24341 Park, 2016, Clinical outcome and predictive factors in the response to splenectomy in elderly patients with primary immune thrombocytopenia: a multicenter retrospective study, Acta Haematol, 135, 162, 10.1159/000442703 Tada, 2018, Long-term outcomes of laparoscopic versus open splenectomy for immune thrombocytopenia, Surg Today, 48, 180, 10.1007/s00595-017-1570-2 Chater, 2016, Reemergence of splenectomy for ITP second-line treatment?, Ann Surg, 264, 772, 10.1097/SLA.0000000000001912 Moulis, 2014, Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity, Am J Hematol, 89, 41, 10.1002/ajh.23580 Vecchio, 2013, Long-term results after splenectomy in adult idiopathic thrombocytopenic purpura: comparison between open and laparoscopic procedures, J Laparoendosc Adv Surg Tech A, 23, 192, 10.1089/lap.2012.0146 Sarpatwari, 2010, Autologous 111 In-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP Registry, Br J Haematol, 151, 477, 10.1111/j.1365-2141.2010.08377.x Cuker, 2010, Evidence-based mini-review: is indium-labeled autologous platelet scanning predictive of response to splenectomy in patients with chronic immune thrombocytopenia?, Hematology (Am Soc Hematol Educ Program), 2010, 385, 10.1182/asheducation-2010.1.385 Mahevas, 2019, Autologous111 indium-oxinate-labelled platelet sequestration study in patients with immune thrombocytopenia treated by thrombopoietin receptor-agonists, Br J Haematol, 186, e44, 10.1111/bjh.15890 Palandri, 2014, The choice of second-line therapy in steroid-resistant immune thrombocytopenia: role of platelet kinetics in a single-centre long-term study, Am J Hematol, 89, 1047, 10.1002/ajh.23823 Qu, 2014, Long-term outcomes of laparoscopic splenectomy versus open splenectomy for idiopathic thrombocytopenic purpura, Int Surg, 99, 286, 10.9738/INTSURG-D-13-00175.1 Mohamed, 2010, Systemic thromboembolic complications after laparoscopic splenectomy for idiopathic thrombocytopenic purpura in comparison to open surgery in the absence of anticoagulant prophylaxis, Hematol Oncol Stem Cell Ther, 3, 71, 10.1016/S1658-3876(10)50038-4 Ray, 2012, Laparoscopic versus open splenectomy in the treatment of idiopathic thrombocytopenic purpura: an Indian experience, J Indian Med Assoc, 110, 889 Chakravarty, 2011, Pregnancy outcomes after maternal exposure to rituximab, Blood, 117, 1499, 10.1182/blood-2010-07-295444 Thai, 2016, Long-term complications of splenectomy in adult immune thrombocytopenia, Medicine (Baltimore), 95, e5098, 10.1097/MD.0000000000005098 Morbieu, 2018, Systematic detection of portal or splenic vein thrombosis after splenectomy for immune cytopenia, Am J Hematol, 93, E170, 10.1002/ajh.25120 Kristinsson, 2014, Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up, Haematologica, 99, 392, 10.3324/haematol.2013.092460 Togasaki, 2018, Long-term efficacy of partial splenic embolization for the treatment of steroid-resistant chronic immune thrombocytopenia, Ann Hematol, 97, 655, 10.1007/s00277-018-3232-x Lakhwani, 2017, Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: a retrospective collaborative survey involving 4 Spanish centres, Eur J Haematol, 99, 372, 10.1111/ejh.12932 González-Porras, 2015, Use of eltrombopag after romiplostim in primary immune thrombocytopenia, Br J Haematol, 169, 111, 10.1111/bjh.13266 Thanarajasingam, 2011, Accessory splenectomy for refractory immune thrombocytopenic purpura, Am J Hematol, 86, 520, 10.1002/ajh.22011 Choi, 2008, Laparoscopic accessory splenectomy for recurrent idiopathic thrombocytopenic purpura, JSLS, 12, 314 Arnold, 2010, Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura, Blood, 115, 29, 10.1182/blood-2009-06-222448 Marsh, 2001, CAMPATH-1H in the treatment of autoimmune cytopenias, Cytotherapy, 3, 189, 10.1080/146532401753174133 Gómez-Almaguer, 2010, Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias, Blood, 116, 4783, 10.1182/blood-2010-06-291831 Lete, 2008, The levonorgestrel intrauterine system (Mirena) for treatment of idiopathic menorrhagia. Assessment of quality of life and satisfaction, Eur J Contracept Reprod Health Care, 13, 231, 10.1080/13625180802075075 Care, 2018, Severe primary autoimmune thrombocytopenia in pregnancy: a national cohort study, BJOG, 125, 604, 10.1111/1471-0528.14697 Loustau, 2014, Effect of pregnancy on the course of immune thrombocytopenia: a retrospective study of 118 pregnancies in 82 women, Br J Haematol, 166, 929, 10.1111/bjh.12976 Reese, 2018, Platelet counts during pregnancy, N Engl J Med, 379, 32, 10.1056/NEJMoa1802897 Reese, 2019, Platelet sequestration and consumption in the placental intervillous space contribute to lower platelet counts during pregnancy, Am J Hematol, 94, E8, 10.1002/ajh.25321 Zhang, 2016, Thrombopoietin: a potential diagnostic indicator of immune thrombocytopenia in pregnancy, Oncotarget, 7, 7489, 10.18632/oncotarget.7106 Wang, 2017, Thrombocytopenia in pregnancy with different diagnoses: differential clinical features, treatments, and outcomes, Medicine (Baltimore), 96, e7561, 10.1097/MD.0000000000007561 Kasai, 2015, Clinical features of gestational thrombocytopenia difficult to differentiate from immune thrombocytopenia diagnosed during pregnancy, J Obstet Gynaecol Res, 41, 44, 10.1111/jog.12496 Michel, 2003, Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy, Br J Haematol, 123, 142, 10.1046/j.1365-2141.2003.04567.x Sun, 2016, Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy, Blood, 128, 1329, 10.1182/blood-2016-04-710285 Kong, 2017, A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy, Blood, 130, 1097, 10.1182/blood-2017-01-761262 Natekar, 2011, Safety of azathioprine use during pregnancy, Can Fam Physician, 57, 1401 CELLCEPT, 2019, CELLCEPT® (mycophenolate mofetil) capsules, for oral use; CELLCEPT® (mycophenolate mofetil) tablets, for oral use; CELLCEPT® Oral Suspension (mycophenolate mofetil), for oral suspension; CELLCEPT® Intravenous (mycophenolate mofetil) for injection, for intravenous use Moudi, 2013, Vinca alkaloids, Int J Prev Med, 4, 1231 Purushothaman, 2016, A case of refractory immune thrombocytopenia in pregnancy managed with elthrombopag, Asian J Transfus Sci, 10, 155, 10.4103/0973-6247.177204 Decroocq, 2014, Rescue therapy with romiplostim for refractory primary immune thrombocytopenia during pregnancy, Obstet Gynecol, 124, 481, 10.1097/AOG.0000000000000371 Patil, 2013, Use of a thrombopoietin mimetic for chronic immune thrombocytopenic purpura in pregnancy, Obstet Gynecol, 122, 483, 10.1097/AOG.0b013e31828d5b56 Suzuki, 2018, A low birth weight infant with no malformations delivered by a primary immune thrombocytopenia patient treated with eltrombopag, Int J Hematol, 108, 109, 10.1007/s12185-017-2383-1 Alkaabi, 2012, Successful treatment of severe thrombocytopenia with romiplostim in a pregnant patient with systemic lupus erythematosus, Lupus, 21, 1571, 10.1177/0961203312463621 Rosa María, Use of romiplostim during pregnancy as a rescue therapy in primary immune thrombocytopenia: literature review and case description [published online ahead of print 22 May 2019], Platelets Ferreira, 2018, Severe immune thrombocytopenia in pregnancy treated with eltrombopag - a case report, J Gynecol Obstet Hum Reprod, 47, 405, 10.1016/j.jogoh.2018.06.010 Lee, 2017, Risk of epidural hematoma after neuraxial techniques in thrombocytopenic parturients: a report from the Multicenter Perioperative Outcomes Group, Anesthesiology, 126, 1053, 10.1097/ALN.0000000000001630 Payne, 1997, Maternal characteristics and risk of severe neonatal thrombocytopenia and intracranial hemorrhage in pregnancies complicated by autoimmune thrombocytopenia, Am J Obstet Gynecol, 177, 149, 10.1016/S0002-9378(97)70454-X Bader-Meunier, 2003, Misdiagnosis of chronic thrombocytopenia in childhood, J Pediatr Hematol Oncol, 25, 548, 10.1097/00043426-200307000-00010 Kottayam, 2007, Isolated thrombocytopenia in children: thinking beyond idiopathic thrombocytopenic purpura and leukaemia, J Paediatr Child Health, 43, 848, 10.1111/j.1440-1754.2007.01240.x Kalpatthi, 2008, Diagnosis, pathophysiology and management of children with refractory immune thrombocytopenic purpura, Curr Opin Pediatr, 20, 8, 10.1097/MOP.0b013e3282f45bb9 Noris, 2013, Platelet size for distinguishing between inherited thrombocytopenias and immune thrombocytopenia: a multicentric, real life study, Br J Haematol, 162, 112, 10.1111/bjh.12349 Celik, 2013, Comparison of anti-D immunoglobulin, methylprednisolone, or intravenous immunoglobulin therapy in newly diagnosed pediatric immune thrombocytopenic purpura, J Thromb Thrombolysis, 35, 228, 10.1007/s11239-012-0801-z Grimaldi-Bensouda, 2017, Childhood immune thrombocytopenia: a nationwide cohort study on condition management and outcomes, Pediatr Blood Cancer, 64, e26389, 10.1002/pbc.26389 Kubota, 2010, Characterization of chronic idiopathic thrombocytopenic purpura in Japanese children: a retrospective multi-center study, Int J Hematol, 91, 252, 10.1007/s12185-009-0484-1 Klaassen, 2001, Initial bone marrow aspiration in childhood idiopathic thrombocytopenia: decision analysis, J Pediatr Hematol Oncol, 23, 511, 10.1097/00043426-200111000-00009 Russo, 2011, Effect of eradication of Helicobacter pylori in children with chronic immune thrombocytopenia: a prospective, controlled, multicenter study, Pediatr Blood Cancer, 56, 273, 10.1002/pbc.22770 Treepongkaruna, 2009, Absence of platelet recovery following Helicobacter pylori eradication in childhood chronic idiopathic thrombocytopenic purpura: a multi-center randomized controlled trial, Pediatr Blood Cancer, 53, 72, 10.1002/pbc.21991 Grainger, 2012, Changing trends in the UK management of childhood ITP, Arch Dis Child, 97, 8, 10.1136/adc.2010.184234 Bennett, 2018, Predictors of remission in children with newly diagnosed immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group Registry II participants, Pediatr Blood Cancer, 65, e26736, 10.1002/pbc.26736 Elalfy, 2010, Intracranial hemorrhage in acute and chronic childhood immune thrombocytopenic purpura over a ten-year period: an Egyptian multicenter study, Acta Haematol, 123, 59, 10.1159/000262293 Kime, 2013, Patterns of inpatient care for newly diagnosed immune thrombocytopenia in US children’s hospitals, Pediatrics, 131, 880, 10.1542/peds.2012-2021 Neunert, 2013, Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS), Blood, 121, 4457, 10.1182/blood-2012-12-466375 Kühne, 2011, Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group, Haematologica, 96, 1831, 10.3324/haematol.2011.050799 Heitink-Pollé, 2018, Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial, Blood, 132, 883, 10.1182/blood-2018-02-830844 Su, 2009, A retrospective analysis of therapeutic responses to two distinct corticosteroids in 259 children with acute primary idiopathic thrombocytopenic purpura, Hematology, 14, 286, 10.1179/102453309X12473408860343 Kane, 2010, Comparison of intravenous immune globulin and high dose anti-D immune globulin as initial therapy for childhood immune thrombocytopenic purpura, Br J Haematol, 149, 79, 10.1111/j.1365-2141.2009.08057.x Papagianni, 2011, Standard-dose intravenous anti-D immunoglobulin versus intravenous immunoglobulin in the treatment of newly diagnosed childhood primary immune thrombocytopenia, J Pediatr Hematol Oncol, 33, 265, 10.1097/MPH.0b013e31820e2aa5 Elalfy, 2017, A randomized multicenter study: safety and efficacy of mini-pool intravenous immunoglobulin versus standard immunoglobulin in children aged 1-18 years with immune thrombocytopenia, Transfusion, 57, 3019, 10.1111/trf.14301 Alioglu, 2013, A comparison of intravenous immunoglobulin (2 g/kg totally) and single doses of anti-D immunoglobulin at 50 μg/kg, 75 μg/kg in newly diagnosed children with idiopathic thrombocytopenic purpura: Ankara hospital experience, Blood Coagul Fibrinolysis, 24, 505, 10.1097/MBC.0b013e32835e5337 Kjaersgaard, 2009, Subcutaneous anti-D treatment of idiopathic thrombocytopenic purpura in children, Pediatr Blood Cancer, 53, 1315, 10.1002/pbc.22248 Payen, 2016, Reduced mortality by meeting guideline criteria before using recombinant activated factor VII in severe trauma patients with massive bleeding, Br J Anaesth, 117, 470, 10.1093/bja/aew276 Shim, 2014, Natural course of childhood chronic immune thrombocytopenia using the revised terminology and definitions of the international working group: a single center experience, Blood Res, 49, 187, 10.5045/br.2014.49.3.187 Neunert, 2016, Thrombopoietin receptor agonist use in children: data from the Pediatric ITP Consortium of North America ICON2 Study, Pediatr Blood Cancer, 63, 1407, 10.1002/pbc.26003 Bussel, 2015, Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study, Lancet Haematol, 2, e315, 10.1016/S2352-3026(15)00114-3 Grainger, 2015, Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial, Lancet, 386, 1649, 10.1016/S0140-6736(15)61107-2 Tarantino, 2016, Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study, Lancet, 388, 45, 10.1016/S0140-6736(16)00279-8 Bussel, 2011, A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia, Blood, 118, 28, 10.1182/blood-2010-10-313908 Elalfy, 2011, Romiplostim in children with chronic refractory ITP: randomized placebo controlled study, Ann Hematol, 90, 1341, 10.1007/s00277-011-1172-9 Bussel, 2015, Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP), Pediatr Blood Cancer, 62, 208, 10.1002/pbc.25136 Grace, 2012, Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia, Pediatr Blood Cancer, 58, 221, 10.1002/pbc.23130 Parodi, 2009, Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response, Br J Haematol, 144, 552, 10.1111/j.1365-2141.2008.07487.x Mueller, 2009, One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab, Pediatr Blood Cancer, 52, 259, 10.1002/pbc.21757 Dierickx, 2009, Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study, J Intern Med, 266, 484, 10.1111/j.1365-2796.2009.02126.x Oved, 2017, Treatment of children with persistent and chronic idiopathic thrombocytopenic purpura: 4 infusions of rituximab and three 4-day cycles of dexamethasone, J Pediatr, 191, 225, 10.1016/j.jpeds.2017.08.036 Miano, 2016, Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian Association of Paediatric Haematology/Oncology, Br J Haematol, 175, 490, 10.1111/bjh.14261 Suvajdzic, 2014, Health-related quality of life in adult patients with chronic immune thrombocytopenia in Serbia, Platelets, 25, 467, 10.3109/09537104.2013.831065 Cooper, 2018, The burden of disease and impact of immune thrombocytopenia (ITP) on patient quality of life and productivity: results from the ITP world impact survey (I-WISH), EHA Library, PF654 Kruse, 2018, Patients with immune thrombocytopenia (ITP) frequently experience severe fatigue but is it under-recognized by physicians: results from the ITP World Impact Survey (I-WISh), Blood, 132, 2273, 10.1182/blood-2018-99-112378 International ITP Alliance. Global ITP support ambassadors. Available at: http://globalitp.org/index.php/patient-support. Accessed 15 October 2019. Trotter, 2018, Immune thrombocytopenia: improving quality of life and patient outcomes, Patient Relat Outcome Meas, 9, 369, 10.2147/PROM.S140932 Sanz, 2011, Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP), Value Health, 14, 90, 10.1016/j.jval.2010.10.017 Efficace, 2016, Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease, Am J Hematol, 91, 995, 10.1002/ajh.24463 Khelif, 2019, Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: findings from the EXTEND study, Am J Hematol, 94, 200, 10.1002/ajh.25348 Mathias, 2009, Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences, Curr Med Res Opin, 25, 375, 10.1185/03007990802634119 Guidry, 2009, Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives, Eur J Haematol, 83, 175, 10.1111/j.1600-0609.2009.01265.x George, 2009, Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials, Br J Haematol, 144, 409, 10.1111/j.1365-2141.2008.07464.x Klaassen, 2007, Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the Kids’ ITP Tools, J Pediatr, 150, 510, 10.1016/j.jpeds.2007.01.037 Klaassen, 2012, Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP), Pediatr Blood Cancer, 58, 395, 10.1002/pbc.23312 Heitink-Pollé, 2014, Health-related quality of life in children with newly diagnosed immune thrombocytopenia, Haematologica, 99, 1525, 10.3324/haematol.2014.106963 Grainger, 2013, Quality of life in immune thrombocytopenia following treatment, Arch Dis Child, 98, 895, 10.1136/archdischild-2013-303784 Mathias, 2016, A phase 3, randomized, double-blind, placebo-controlled study to determine the effect of romiplostim on health-related quality of life in children with primary immune thrombocytopenia and associated burden in their parents, Pediatr Blood Cancer, 63, 1232, 10.1002/pbc.25984 Grainger, 2019, Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study, Br J Haematol, 185, 102, 10.1111/bjh.15732 Kumar, 2015, Sports participation in children and adolescents with immune thrombocytopenia (ITP), Pediatr Blood Cancer, 62, 2223, 10.1002/pbc.25644 Howell, 2017, Sports participation recommendations for patients with bleeding disorders, Transl Pediatr, 6, 174, 10.21037/tp.2017.04.07